CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 ...
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 ...
Milestone Pharmaceuticals hit another bump in the road in its quest to get Cardamyst approved for paroxysmal supraventricular ...
Stocktwits on MSN9h
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s PositiveShares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...
The company expects to meet with the FDA in Q2 2025 to finalize analysis plans for biomarker data, with a potential accelerated NDA submission in the second half of 2025. Clene ended the year with ...
NDA submission is anticipated to occur in the second half of 2025. Additionally, the FDA indicated that the decision as to whether NfL can serve as a reasonably likely surrogate endpoint for the ...
Commercial Metals Company manufactures, recycles, and fabricates steel and metal products, and related materials and services in the United States, Poland, China, and internationally. It operates ...
White Lotus fans couldn't stop talking about the racy scenes involving Sam Nivola's character — and it turns out neither could he. In an interview with Variety published online on Sunday, March ...
Tonix Pharmaceuticals has submitted an NDA for its candidate TNX-102 SL for ... According to the company's 2024 10K submission, discussing TNX-102 competition, Tonix states: Lyrica is now marketed ...
Takeda Pharmaceuticals and Lundbeck have jointly announced the submission of a New Drug Application (NDA) to the US FDA for the investigational agent vortioxetine. Vortioxetine (Lu AA21004 ...
Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2024. Highlights include: MOUNTAIN VIEW, Calif ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback